COMIRNATY can help protect
you
against COVID-19
About the Clinical Trials
Multiple clinical trials contributed to testing COMIRNATY
~46,000 people
participated in the main COMIRNATY clinical trial
The safety and efficacy of COMIRNATY were evaluated in a main clinical trial (called Study 2) of approximately 46,000 people 12 years and older—one of the largest vaccine clinical trials Pfizer has ever conducted. This trial tested the safety of the original formula of COMIRNATY and how well it worked to help protect against COVID-19 and severe disease.
Of the 46,000 in the safety population, approximately 2260 participants were 12 through 15 years of age (1131 COMIRNATY; 1129 placebo). 44,047 participants were 16 years of age or older (22,026 COMIRNATY; 22,021 placebo).
Additional studies assessed the safety and immunogenicity of updated formulas, adapted from the original COMIRNATY. These updated vaccine formulas were designed to help protect against circulating strains of the virus that caused COVID-19 at that time.
Learn More About the Main COMIRNATY Trial
Learn More About the Immunogenicity Studies
Learn More About COMIRNATY Side Effects & Safety
From You